Date: 2011-11-23
Type of information: R&D agreement
Compound: PRX00933, the lead compound from Proximagen’s 5HT2c programme
Company: Proximagen (UK) Altacor (UK)
Therapeutic area: Ophtalmological diseases
Type agreement: R&D
Action mechanism: PRX00933 is an agonist at the 5HT2c receptor
Disease: glaucoma
Details: Proximagen Group, company with a principal focus on the treatment of disorders of the central nervous system, and Altacor, a specialty ophthalmic pharmaceutical company, have signed a Collaborative Research and Development Agreement.
Under the terms of the Agreement Altacor will undertake the research and development of PRX00933, the lead compound from Proximagen’s 5HT2c programme, to treat glaucoma. Altacor also gains an option for exclusive global rights to ophthalmic indications with Proximagen retaining all rights outside of ophthalmology.
PRX00933.is an agonist at the 5HT2c receptor and has the potential to treat obesity, diabetes, epilepsy, urinary incontinence, and psychiatric and ophthalmology disorders. The compound was initially developed as a targeted approach for controlling the brain’s satiety centre and thus achieving weight control. PRX00933 has been dosed in over 480 subjects, was shown to be safe and well tolerated, and in a randomised, placebo controlled, double blind phase II study demonstrated significant weight reduction in patients.
5HT2c agonists have recently shown promise as a new treatment of glaucoma by reducing intraocular pressure in industry standard models of glaucoma, a chronic condition that results in progressive loss of vision and which is the second most common cause of blindness. So, Altacor and Proximagen will conduct a programme of collaborative research to develop PRX00933 in glaucoma and will use the existing clinical package to facilitate the development.
Financial terms: Financial terms were not disclosed.
Latest news:
